Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
713 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT02807636 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma(IMvigor130) | completed | Phase 3 | 1,213 | Hoffmann-La RocheINDUSTRY |
| 35 |
| Feb 24, 2025 |
| clinicaltrials |
| NCT03452111 | Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception | completed | Phase 2 | 420 | Premier ResearchOTHER | 7 | Feb 18, 2025 | clinicaltrials |
| NCT02437318 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.(SOLAR-1) | completed | Phase 3 | 572 | Novartis PharmaceuticalsINDUSTRY | 31 | Feb 13, 2025 | clinicaltrials |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | completed | Phase 2 | 274 | Bristol-Myers SquibbINDUSTRY | 17 | Feb 5, 2025 | clinicaltrials |
| NCT01715285 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | completed | Phase 3 | 1,209 | Janssen Research & Development, LLCINDUSTRY | 33 | Feb 4, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT06529302 | The OPBC-07/microNAC Study | active not recruiting | — | 2,000 | University Hospital, Basel, SwitzerlandOTHER | 30 | Jan 24, 2025 | clinicaltrials |
| NCT06766903 | Onco-Vascular Exer-Study | completed | N/A | 30 | Cristian AlvarezOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT02167490 | Sentinel Node Vs Observation After Axillary Ultra-souND(SOUND) | active not recruiting | N/A | 1,560 | European Institute of OncologyOTHER | 4 | Nov 25, 2024 | clinicaltrials |
| NCT02635672 | Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | completed | Phase 1 | 110 | Vincerx Pharma, Inc.INDUSTRY | 3 | Nov 15, 2024 | clinicaltrials |
| NCT01084252 | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 351 | SanofiINDUSTRY | 17 | Nov 1, 2024 | clinicaltrials |
| NCT04456699 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | completed | Phase 3 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Oct 29, 2024 | clinicaltrials |
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | completed | Phase 3 | 749 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Oct 15, 2024 | clinicaltrials |
| NCT03447769 | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A(Canopy-A) | terminated | Phase 3 | 1,382 | Novartis PharmaceuticalsINDUSTRY | 41 | Oct 9, 2024 | clinicaltrials |
| NCT00072462 | Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ(IBIS-II DCIS) | completed | Phase 3 | 2,980 | Queen Mary University of LondonOTHER | 14 | Sep 19, 2024 | clinicaltrials |
| NCT03668119 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)(CheckMate 848) | completed | Phase 2 | 212 | Bristol-Myers SquibbINDUSTRY | 17 | Aug 28, 2024 | clinicaltrials |
| NCT05447988 | Motiva Flora Tissue Expander PMCF | unknown | N/A | 136 | Establishment LabsINDUSTRY | 4 | Aug 27, 2024 | clinicaltrials |
| NCT06556004 | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients(Trimelvax001) | unknown | Phase 1 | 20 | University of ChileOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04152863 | Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011) | terminated | Phase 2 | 85 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 6, 2024 | clinicaltrials |
| NCT03830866 | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)(CALLA) | completed | Phase 3 | 770 | AstraZenecaINDUSTRY | 15 | Jul 26, 2024 | clinicaltrials |
| NCT06501261 | CALM Psychotherapy in Patients With Metastatic Cancer in Chile(CALM-Ch) | unknown | N/A | 34 | Fundacion Arturo Lopez PerezOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06260111 | Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation(POMFITT) | unknown | N/A | 30 | Universidad del DesarrolloOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | completed | Phase 3 | 433 | ImmunityBio, Inc.INDUSTRY | 13 | Jun 13, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT06432426 | Virtual Exercise on Elderly Breast Cancer Survivors | unknown | N/A | 60 | Pontificia Universidad Catolica de ChileOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT02899299 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients(CheckMate743) | completed | Phase 3 | 605 | Bristol-Myers SquibbINDUSTRY | 21 | May 21, 2024 | clinicaltrials |
| NCT05690295 | Resistance-type Exercise Training in Postmenopausal Women Survivors of Breast Cancer(MUSCLE-CLIM) | completed | N/A | 26 | Universidad de La FronteraOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT03957031 | Gastric Cancer Risk Factors Associated With EU and CELAC Populations(LEGACY-1) | completed | — | 1,600 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT04015466 | Advanced GC Multi-omic Characterization in EU and CELAC Populations(LEGACY-2) | completed | — | 800 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT04019808 | Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population(LEGACY-3) | completed | — | 800 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 7 | May 9, 2024 | clinicaltrials |
| NCT00110110 | Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma | unknown | Phase 2 | 71 | The Hospital for Sick ChildrenOTHER | 4 | Apr 17, 2024 | clinicaltrials |
| NCT06077123 | Telemonitoring Platforms and Chemotherapy-Associated Toxicity(DETECT) | unknown | N/A | 80 | Universidad Nacional Andres BelloOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT06086990 | Effects of Telemonitoring in Quality of Life Amongst Cancer Patients(EQUALITE) | unknown | N/A | 80 | Universidad Nacional Andres BelloOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT04896242 | Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients | completed | — | 47 | Pontificia Universidad Catolica de ChileOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05123391 | Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer | unknown | N/A | 60 | Pontificia Universidad Catolica de ChileOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03337724 | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer(IPATunity130) | completed | Phase 3 | 579 | Hoffmann-La RocheINDUSTRY | 30 | Mar 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials